Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
featured
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer  

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination

measurable disease
palbociclib
erbb2
letrozole
HER2
  • 24 views
  • 09 Sep, 2021
  • 4 locations
Capivasertib + Palbociclib + Fulvestrant for HR+/HER2- Advanced Breast Cancer (CAPItello-292).

A Phase Ib/III Randomised Study of Capivasertib plus Palbociclib and Fulvestrant versus Placebo plus Palbociclib and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor

  • 0 views
  • 09 Sep, 2021
  • 18 locations
Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant

the combination of Fulvestrant plus Palbociclib as neoadjuvant therapy of hormone-sensitive patients with operable luminal breast cancer. Eligible patients will be assessed upfront using the

fulvestrant
palbociclib
goserelin 3.6 mg
endocrine therapy
renal function
  • 161 views
  • 22 Jan, 2021
  • 14 locations
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer

at different times. The study will aim to do a descriptive analysis of omics profiles evolution (tumor, volatile organic components) over time, before and after disease progression under Palbociclib

  • 0 views
  • 27 Jan, 2021
  • 1 location
Palbociclib Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer. It is hypothesised that

measurable disease
metastatic carcinoma
local therapy
palbociclib
platelet count
  • 45 views
  • 24 Jan, 2021
  • 3 locations
A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. To evaluate the antitumor activity of …

  • 0 views
  • 20 Sep, 2021
  • 1 location
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+ HER2- Advanced Breast Cancer Patients (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

measurable disease
abemaciclib
her2-negative breast cancer
cish
aromatase inhibitor
  • 0 views
  • 19 Jul, 2021
  • 49 locations
Adjuvant Palbociclib in Elderly Patients With Breast Cancer

Phase II study to assess the efficacy of the combination of at least 5 year endocrine therapy and 2 year-palbociclib as adjuvant systemic treatment instead of adjuvant chemotherapy followed by

paclitaxel
human epidermal growth factor
anthracyclines
endocrine therapy
metastasis
  • 4 views
  • 07 Aug, 2021
  • 76 locations
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with

measurable disease
palbociclib
erbb2
metastasis
HER2
  • 0 views
  • 08 Jul, 2021
  • 197 locations
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

This is a phase II, multi-center, single-arm, open-label trial to evaluate efficacy of palbociclib with endocrine therapy as adjuvant treatment in women with C-high/G-high risk ER-positive/HER2

palbociclib
primary tumor
hormone therapy
erbb2
endocrine therapy
  • 0 views
  • 24 Jan, 2021
  • 1 location